Our patented electrochemical sensing platform allows for home-based, simultaneous detection of multiple biomarkers such as glucose, lactate, cholesterol, liposome, dopamine, DNA, bacteria, viruses, and proteins such as immunoglobulin G – even when they’re present in very small quantities (order of a femtomole, 10-15).
Single-use strips, carrying a set of electrochemical sensors – the heart of OMINI technology
A connected portable reader, capable of reading, converting and displaying the signals coming from the strips
Online services for data storage and tracking
Simplicity: a drop of the patient's blood, taken by finger prick, is placed on the single-use chip that analyzes the sample. The chip is then inserted into the electronic reading device, before the value is finally read and displayed on screen – or sent directly to online services.
Modularity: by changing the biological recognition element on the surface, OMINI testing devices can be modified to measure a very wide variety of biomarkers.
Watch the animation to dive deeper into how our technology enables decentralized blood testing, and what the testing process looks like end-to-end.
Our first product: improving heart failure outcomes
Heart failure is a chronic, non-curable disease that currently affects around 60 million patients worldwide. The traditional heart-failure patient journey is fragmented and unpredictable, often resulting in last-minute hospital readmissions which cause distress in patients, while putting a further strain on hospital resources.
At OMINI, we want to transform the heart-failure patient journey for the better. It’s why, in collaboration with top cardiologists, we’re now developing a home-based, multisensing strip that simultaneously detects four key biomarkers relevant to heart failure from a single drop of blood.
The benefits are four-fold:
Patient stability for longer periods of time
Reduced hospital readmissions
Improved quality of life and survival chances
Improved processes for patient management